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New substituted pyrrolidine-3,4-diol derivatives were prepared from D-(-)- and L-(+)-phenyl
glycinol. The influence of the configuration and the substitution of the lateral side chain of
these derivatives on the inhibition of 25 commercial glycosidases were determined. (2R,3R,4S)-
2-({[(1R)-2-Hydroxy-1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol ((+)-7a) was a potent and
selective inhibitor of jack bean R-mannosidase (Ki ) 135 nM). However, when evaluated on
human tumor cells, 7a, and the reference compound swainsonine, did not efficiently inhibit
the growth of glioblastoma cells. Further derivatization of the hydroxyl group with lipophilic
groups to increase bioavailability improved their growth inhibitory properties for human
glioblastoma and melanoma cells. In particular, the 4-bromobenzoyl derivative 26 demonstrated
high efficacy for human tumor cells whereas primary human fibroblasts were less sensitive to
26. Therefore, functionalized pyrrolidines have the potential to inhibit the growth of tumor
cells and display selectivity for tumor cells when compared to normal cells.
Introduction
Very few therapeutic options exist for the treatment
of human glioblastoma and metastatic melanoma, in
part because of their resistance to chemotherapeutic
agents.1 Therefore, new drugs have to be developed that
are able to overcome resistance, and such novel ap-
proaches may be represented by agents targeting the
glycosylation pathways of cancer cells. Aberrant glyco-
sylation of glycoproteins and glycolipids was reported
to be one of the molecular changes that accompany
malignant transformations.2 As both catabolic and
processing glycosidases are involved in the transforma-
tion of normal cells to cancer cells and in tumor cell
invasion and migration,3 it has been proposed that the
specific inhibition of R-mannosidases involved in the
addition of N-linked carbohydrates to glycoproteins may
provide a new anticancer strategy4-6 able to overcome
resistance to conventional chemotherapeutic agents.
Clinical trials have demonstrated that swainsonine, a
natural inhibitor of Golgi R-mannosidase II, which
contains a 4-amino-4-deoxy-mannofuranoside moiety,7
decreases the growth of solid tumors and hematological
malignancies.8 In particular, Kino and co-workers were
the first to report that the subcutaneous administration
of swainsonine completely inhibited the growth and the
formation of lung metastases of a sarcoma.9 Neverthe-
less, the toxicity observed for this alkaloid as well as
the undesired coinhibition of lysosomal fucosidases
resulted in the search for new, more selective R-man-
nosidases inhibitors. Some analogues of swainsonine
such as 2 (Chart 1) as well as simpler derivatives have
shown interesting inhibitory properties.10-12 We previ-
ously reported that 3,4-dihydroxy-pyrrolidin-2-yl deriva-
tives such as 3 and 4 are selective and competitive
inhibitors of R-mannosidase from the jack bean.13,14
Recently, we reported that 2-aminomethyl-5-(hydroxy-
methyl)pyrrolidine-3,4-diol derivatives of type 4 are
competitive inhibitors of R-mannosidases with higher
potency than the corresponding diamines with no sub-
stituent at the C(5) position of the pyrrolidine ring.15
However, the potential of these molecules to inhibit
tumor cell growth was not evaluted.
Here we report the synthesis and characterization of
new derivatives of the diamine 3a where a hydroxy-
methyl substituent was introduced on the lateral side
chain of pyrrolidine and was able to inhibit purified
glycosidases at low concentration. The effect of these
derivatives on the proliferation of human glioblastoma
and melanoma cells, two tumors associated with a high-
proliferative and invasive potential, multiple resistance
toward conventional chemotherapeutic agents, and poor
prognosis, and on human fibroblasts as models for
nontumoral cells was also determined. Drug resistance
may result from the expression by tumor cells of enzyme
systems able to reverse the cytostatic or cytotoxic effect
of these agents or from the expression of efflux pumps
able to extrude these agents out of tumor cells. There-
fore novel strategies, which must be able to reverse
tumor resistance to chemotherapeutic agents, have to
be envisioned to treat these cancers. We have previously
shown that molecules unrelated to conventional thera-
peutic agents, such as the drugs targeting the endo-
thelin16,17 and the renin-angiotensin18 systems, or
carbohydrate analogues,19 may be of some interest.
In this context, agents able to modify the glycosyla-
tion pathways of tumor cells may be particularly
valuable.
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Results and Discussion
Synthesis. The fully protected carbaldehyde 520 was
submitted to a reductive amination procedure in the
presence of phenylglycinol derivatives and sodium tri-
acetoxyborohydride for an in situ reduction of the so-
formed imines (Scheme 1). Acidic treatment of protected
derivatives 6 afforded diamines 7a-7d with a 40-74%
yield (two steps). The previously reported alcohol 821
was oxidized under Swern conditions and treated as
above with D-(-)-R-phenylglycinol to provide diamine
10, bearing two hydroxymethyl groups, with a 65% yield
(three steps).
Functionalization of the primary alcohol of derivative
7a was also performed in order to investigate the role
of this hydroxyl moiety in enzyme recognition. D-(-)-R-
phenylglycinol was transformed into diallylamine 11
with an 85% yield, allowing protection of the primary
alcohol as simple ethers (benzyl and methyl ethers) with
good to quantitative yields. Substituted benzyl ethers
were also introduced. Palladium promoted cleavage of
the allyl moieties in the presence of 2-mercaptobenzoic
acid as an allyl scavenger,21 followed by a reductive
amination procedure with carbaldehyde 5, led to di-
amines 18 and 19, after quantitative deprotection in
acidic medium. Deallylation of the 3-fluorobenzyl ether
resulted in a poor yield of the corresponding amine 17,
which was then submitted to the same sequence of
reductive amination/acidic deprotection to provide the
functionalized pyrrolidine 20 in 40% yield.
Further derivatives containing lipophilic esters were
prepared in order to determine whether modification of
the hydroxyl group would improve efficacy (Scheme 2).
Moreover, the introduction of lipophilic aromatic moi-
eties should improve cell membrane penetration. D-(-
)-R-Phenylglycinol was protected as a tert-butyl carbam-
ate (21), allowing acylation of the primary alcohol with
substituted aromatic acyl chlorides. After acidic treat-
ment, the resulting amines were also engaged in a
reductive amination procedure with pyrrolidine carbal-
dehyde 5 to provide compounds 23-26 after quantita-
tive cleavage of the Boc and acetonide protecting groups.
Intermediate 21 was also converted into the correspond-
ing azido derivative which was used to introduce amide
groups on the lateral side chain of the pyrrolidine such
as the substituted benzamide 29.
Inhibition of Purified Plant Glycosidases. The
inhibitory potential of compounds 7a-7d, 10, 18-20,
23-26, and 29 toward 25 commercially available gly-
cosidases22 was determined and compared with the
previously reported pyrrolidine derived inhibitors. The
data are summarized in Table 1. The compounds (at 1
mM concentration) did not inhibit R-L-fucosidases (from
bovine epididymis or human placenta), R- and â-galac-
tosidases (from coffee beans, Aspergillus niger, Aspergil-
lus orizae, Escherichia coli, or jack bean), R- and
â-glucosidases (from yeast, rice, Aspergillus niger, rhizo-
pus mold, almond, or Caldocellum saccharolyticum),
â-mannosidases (from Helix pomatia), â-xylosidase (from
Aspergillus niger), R-N-acetylgalactosaminidase, and
â-N-acetylglucosaminidase (from chicken liver) (results
not shown). However, R-mannosidases from jack bean
and almond were inhibited by these derivatives with a
high selectivity. In particular, the D-(-)-R-phenylglyci-
nol-substituted derivative 7a was a potent (Ki ) 135 nM,
IC50 ) 700 nM), competitive (as determined on a
Lineweaver-Burk plot) inhibitor of jack bean R-man-
nosidase, a reliable model enzyme for mammalian Golgi
R-mannosidases II,23 but was less potent for almond
R-mannosidase. Introduction of an hydroxymethyl group
on the lateral side chain of the pyrrolidine ring led to a
considerable increase of the inhibitory potential in
comparison with the nonsubstituted derivative 3a (IC50
) 60 íM for 3a vs IC50 ) 700 nM for 7a, factor of
increase ) 85). Its diastereoisomer 7b was much less
active (IC50 ) 100 íM), demonstrating the influence of
the stereochemistry of the lateral side chain of the
pyrrolidine for optimal recognition by the enzyme.
Introduction of a second aromatic group (7c and 7d)
resulted in a significant decrease of the inhibition of
both R-mannosidases. The steric hindrance of these
derivatives may be too important to allow them to enter
the active site of the enzyme.
The free hydroxyl group on the lateral side chain
seemed to also be a determinant for inhibition since the
introduction of a methyl ether (18) led to a drastic loss
of inhibitory activity (77% and 63% inhibition at 1 mM
for R-mannosidases from the jack bean and almond,
respectively). The benzyl-protected derivative 19 still
presented an inhibition constant of 16 íM (IC50 ) 58
íM) toward R-mannosidase from jack bean (80 times
less active than 7a). The ester and amide derivatives
23-26 and 29 were also less active than the parent
unprotected compound 7a with average IC50 values of
60 íM and a competitive type of inhibition. This can be
explained by an increase of the steric hindrance as well
as the loss of potential hydrogen bonding with the active
site of the enzyme. Finally, introduction of a second
hydroxymethyl group (compound 10) improved the
inhibitory potential on R-mannosidase from almond
(IC50 ) 3.0 íM, Ki ) 600 nM) when compared with
Chart 1. Swainsonine and Pyrrolidine Derivatives as
Inhibitors of R-Mannosidases
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compound 7a. Nevertheless, 10 was less active than 7a
on R-mannosidase from jack bean (Ki ) 1.35 íM).
Evaluation of Functionalized Pyrrolidines in
Human Glioblastoma and Melanoma Cells or Fi-
broblasts. First, the effects of derivatives 3a, 3b, 7a-
7d, and 10 were determined in human LN18 and
LNZ308 glioblastoma cells using the MTT ((3,4,5-
dimethylthiazol-yl)-2,5-diphenyl tetrazolium) assay, which
determines the number of metabolically active cells
present. Derivatives 3a, 7b-7d, and 10 did not display
any activity (results not shown). Compound 3b at 250
íM induced a 23% decrease in the number of metaboli-
Scheme 1. Synthesis of Phenylglycinol Derivatives
Scheme 2. Pyrrolidine Derivatives from Aromatic Phenylglycinol Esters and Amides
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cally active cells. We observed some growth inhibitory
activity of 7a on LN18 and LNZ308 at high concentra-
tion (results not shown); however this compound was
unstable under biological conditions, and we did not
investigate it in more detail. As the hydrophilic char-
acter of these molecules may hinder their transport
across a cell membrane, we prepared more lipophilic
derivatives and evaluated them on the growth of human
glioblastoma cells exposed for 24, 48, or 72 h to these
molecules. These compounds demonstrated a time- and
concentration-dependent inhibition of growth, with 26
being the most rapidly active molecule, producing
almost complete inhibition within 24 h. These results
are summarized in Table 2.
Swainsonine, an R-mannosidase inhibitor with prom-
ising antitumoral properties,4,7-9 only inhibited by 20%
glioblatoma cell growth at 250 íM and was not active
at a lower concentration (Figure 1A). Compound 7a, the
most active inhibitor for plant R-mannosidases, was not
active on human glioblastoma cells. These discrepancies
could result from a poor cell membrane permeability
and a low uptake of these compounds by glioblastoma
cells. Among the lipophilic substituents of the lateral
side chain of 7a, the 4-bromobenzoyl ester 26 was the
most efficient. The replacement of the bromo by a fluoro
(24), or a bromo (25), or a fluoro (23), in position 3 of
the aromatic ring resulted in the loss of antiproliferative
properties. The use of an amide bond rather than an
ester bond to link the bromobenzoyl moiety to the
pyrrolidine backbone, resulting in 29, decreased the
efficacy. 4-Bromobenzoı¨c acid or ethyl 4-bromobenzoate,
which may result from the hydrolysis of 26 by cell
esterases, were without effect on glioblastoma and
melanoma cell growth (results not shown) excluding an
effect from the aromatic substituent. A dose-response
evaluation (300-100 íM) of the antiproliferative effects
of 26 and 29 (parts B and C of Figure 1) in both
glioblastoma cells demonstrated the increased efficacy
of 26 when compared to swainsonine or 29. The IC50
values for 26 and 29 were determined to be 125 and
225 íM in LN 18 and LNZ 308 cells, respectively. These
results suggest that cellular esterases, rather than
peptidases, are able to release the more hydrophilic
derivative 7a with a free terminal alcohol, which was
shown to be the most active and selective mannosidases
inhibitor of this series of pyrrolidine derivatives.
We then evaluated whether 26 has the potential to
diminish cell growth by inhibiting the synthesis of DNA
and/or proteins. The evaluation of the incorporation of
[3H]-thymidine and [3H]-Leu following 6 h of exposure
of the cells to these molecules demonstrated that 26
inhibited thymidine incorporation (DNA synthesis)
(Figure 2A) at slightly lower concentrations and to a
higher extent than inhibiting leucine incorporation
(protein synthesis) (Figure 2B). These results suggest
that this molecule acts initially by inhibiting DNA
synthesis (93% inhibition at 300 íM in LN18), then the
rate of protein synthesis will decrease (82% at 300 íM
in LN18), resulting in diminished cell survival.
Table 3 summarizes and compares the effects on cell
growth (MTT assay) after 24 h of exposure to swainso-
nine, 7a (the best inhibitor for plant R-mannosidases),
and 26 in glioblastoma and melanoma, demonstrating
the increased efficiency of 26; however it has to be
emphasized that relatively high concentrations (>100
íM) must be applied in order to have complete inhibition
Table 1. Inhibitory Activities of Pyrrolidine Derivatives
toward R-Mannosidases from Jack Bean or Almond
inhibitor/
enzyme
R-mannosidase
(jack bean)
R-mannosidase
(almond)
7a 100%a (C)b
IC50 ) 700 nM,
Ki ) 135 nM
93% (C)
IC50 ) 46 íM,
Ki ) 9.5 íM
7b 92%
IC50 ) 100 íM
55%
7c 88%
IC50 ) 110 íM
55%
7d 84%
IC50 ) 128 íM
50%
10 98% (C)
IC50 ) 4.2 íM,
Ki ) 1.35 íM
96% (C)
IC50 ) 3.0 íM,
Ki ) 600 nM
18 77% 63%
19 92% (C)
IC50 ) 58 íM,
Ki ) 16 íM
75%
20 99% (C)
IC50 ) 30 íM,
Ki ) 7 íM
nd
23 83% (C)
IC50 ) 63 íM,
Ki ) 24 íM
nd
24 92% (C)
IC50 ) 60 íM,
Ki ) 19 íM
nd
25 79% nd
26 92%
IC50 ) 55 íM
nd
29 95%
IC50 ) 89 íM
nd
a Percent inhibition at 1 mM and optimal pH. b Competitive
inhibition.
Table 2. Time-course of Growth Inhibition of Glioblastoma
Cellsa by Functionalized Pyrrolidines
LN18 LNZ 308
conc [íM] 24 h 48 h 72 h 24 h 48 h 72 h
7a 300 22 23 22 26 25 22
200 19 26 12 8 19 13
100 13 16 15 0 19 5
7b 300 7 28
200 17 4
100 0 0
20 300 27 39 76 34 56 53
200 19 14 41 14 29 27
100 2 6 12 2 6 6
23 300 26 8 15 23 18 26
200 17 10 14 18 15 17
100 0 7 3 0 6 0
24 300 20 24 31 21 17 32
200 22 16 14 16 18 24
100 9 5 4 4 10 8
25 300 16 29 36 17 31 34
200 10 25 24 5 23 23
100 8 21 18 5 17 13
26 300 92 95 97 87 78 96
200 67 48 68 60 33 56
100 5 17 31 11 15 24
29 300 52 50 65 50 42 59
200 30 46 61 20 40 52
100 15 20 43 2 19 43
a Cells were exposed for 24, 48, or 72 h to 0, 100, 200, or 300
íM of the various synthetic derivatives, then the MTT assay was
performed for the last 2 h of incubation. The percent of residual
mitochondrial activity was calculated as the ratio of treated to
control cells.
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of cell growth, suggesting that the bioavailability of this
series of molecules may be further optimized.
Therefore, 26 was the most promising derivative of
this series in glioblastoma cells. Furthermore, we
determined whether this compound was also able to
inhibit DNA and protein synthesis and survival in
human cancer cells originating from a tumor different
from glioblastoma, the melanoma. Exposure of human
Me237 and Me275 melanoma cells for 6 h to 26 resulted
in a blockade of DNA synthesis (Figure 3A) and protein
synthesis (Figure 3B), and after 24 h, the number of
metabolically active, melanoma cells decreased (Figure
3C), as determined using the MTT assay.
Finally, we evaluated the sensitivity of human fibro-
blasts, as models for nontumoral cells to 26 (Figure 4).
Fibroblasts were less sensitive to this compound than
glioblastoma and melanoma cells for the inhibition of
DNA synthesis after 6 h of exposure (Figure 4A) or
survival after 24 h of exposure (Figure 4B) suggesting
some cell selectivity of 26 between tumoral and nontu-
moral cells.
Conclusion
In conclusion, a series of functionalized pyrrolidine
inhibitors of mannosidases have been prepared and
evaluated. The phenylglycinol derivative 7a was shown
to be a potent, selective and competitive inhibitor of
R-mannosidase from the jack bean (Ki ) 135 nM).
However, it did not inhibit the growth of human tumor
cells. We postulated that its hydrophilic character
prevented its internalization by cells. In support of this
hypothesis, the more lipophilic derivative 26 inhibited
the growth of human glioblastoma and melanoma cells
more than the growth of human fibroblasts and more
efficiently than swainsonine, a potential antitumoral
agent. The presence of lipophilic substituents increased
the efficacy making these derivatives able to inhibit
DNA and protein synthesis and tumor cell survival.
Figure 1. Growth inhibition of human glioblastoma cells by
swainsonine, 26, or 29. Cells were exposed for 24 h to an
increasing concentration of either swainsonine (A), 26 (B), or
29 (C), then the MTT assay was performed for the last 2 h
and the percent of growth was calculated as the ratio of the
MTT reduction of treated to untreated cells. Results are shown
as means ( SD of triplicate wells of one representative
experiment out of three.
Figure 2. Inhibition of DNA and protein synthesis by 26 in
human glioblastoma cells: light gray bars, LN18 and dark
gray bars, LNZ308. Cells were exposed for 6 h to an increasing
concentration of 26. The incorporation of either (A) radioactive
thymidine [3HT] or (B) radioactive leucine [3H]Leu was
performed for the last 2 h. Results are shown as means ( SD
of triplicate wells of one representative experiment out of three.
Table 3. Comparison of Dose Dependency of Growth Inhibition
of Glioblastoma and Melanoma Cellsa by Functionalized
Pyrrolidines
300 íM 200 íM 100 íM
swainsonine LN18 13 18 7
LNZ308 16 24 25
Me275 15 22 14
Me237 20 21 8
compound 7a LN18 22 19 13
LNZ308 26 8 0
Me275 14 16 15
Me237 29 30 16
compound 26 LN18 92 67 5
LNZ308 87 60 11
Me275 100 88 16
Me237 100 98 54
a Cells were exposed for 24 h to either swainsonine, compound
7a, or 26 at 0, 100, 200, or 300 íM, then the MTT assay was
performed for the last 2 h of incubation. The percent of growth
inhibition was calculated by comparing treated to untreated cells.
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Thus the exposure of tumor cells to ester derivatives of
prodrugs analogue of 26 would result in two advan-
tages: the hydrolysis of the ester would release mol-
ecules more active on mannosidases than the prodrugs,
and the hydrophilic character of the active molecules
following its intracellular hydrolysis by esterases would
prevent its passive diffusion out of the cells. Such a
strategy already proved to be efficient for ester deriva-
tives of aminolevulinic acid in the context of photody-
namic therapy protocols.24
Therefore, functionalized pyrrolidines represent prom-
ising lead agents able to control the progression of
human glioblastoma and melanoma, to inhibit DNA and
protein synthesis and tumor cell survival, and to display
some selectivity for tumor cells compared to nontumoral
cells.
Experimental Section
Chemistry. Commercial reagents (Fluka, Aldrich) were
used without purification. Solvents were distilled prior to use:
tetrahydrofuran (THF) from Na and benzophenone, MeOH
from Mg and I2, and CH2Cl2 from CaH2. The light petroleum
ether used refers to the fraction boiling at 40-60 °C. Solutions
after reactions and extractions were evaporated in a rotatory
evaporator under reduced pressure. Liquid/solid flash chro-
matography (FC): columns of silica gel (0.040-0.63 mm, Merck
No. 9385 silica gel 60, 240-400 mesh). Thin-layer chromatog-
raphy (TLC) for reaction monitoring: Merck silica gel 60F254
plates; detection by UV light; Pancaldi reagent ((NH4)6MoO4,
Ce(SO4)2, H2SO4, H2O) or KMnO4. IR spectra: Perkin-Elmer-
1420 spectrometer. 1H NMR spectra: Bruker-ARX-400 spec-
trometer (400 MHz); ä (H) in ppm relative to the solvent’s
residual 1H signal (CHCl3, ä (H) 7.27; CH3OD, ä (H) 3.34) as
internal reference; all 1H assignments were confirmed by 2D-
correlation spectroscopy-45 and 2D-nuclear Overhauser effect
spectrometry spectra. 13C NMR spectra: same instrument as
above (101 MHz); ä (C) in ppm relative to solvent’s C-signal
(CDCl3, ä(C) 77.0; CD3OD, ä(C) 48.5) as internal reference;
coupling constants J in hertz. MS: Nermag R-10-10C, chemical
ionization (NH3) mode m/z (amu) (% relative base peak
(100%)). Electrospray mass spectra were obtained from the
Swiss Institute of Technology Mass Spectral Facility. Elemen-
tal analyses: Ilse Beetz, D-96301 Kronach, Germany. Analyti-
cal high-performance liquid chromatography (HPLC) was
performed on a Waters 600 apparatus, equipped with a Waters
absorbance detector set at 214 nm and C4, C8, and C18 Grace
Vydac columns. Elution was performed using the following
gradient over 30 min, 100% (0.9% TFA in H2O) to 100% (0.9%
TFA in MeCN).
Procedure 1: General Method for the Reductive Ami-
nations. NaBH(OAc)3 (1.4 equiv) was added portionwise to a
stirred solution of aldehyde RCHO (0.1-0.3 M) and primary
Figure 3. Inhibition of growth and DNA synthesis in human
melanoma cells by 26: light gray bars, Me237 and dark gray
bars, Me275. Cells were exposed to an increasing concentration
of 26, either (A) for 6 h and the incorporation of radioactive
thymidine (3HT) was performed for the last 2 h or (B) for 24
h, and the MTT assay was performed for the last 2 h,and the
percent of growth was calculated as the ratio of thymidine
incorporation or MTT reduction of treated to untreated cells.
Results are shown as means ( SD of triplicate wells of one
representative experiment out of three.
Figure 4. Comparison of the growth inhibition induced by
26 in human primary fibroblasts and human tumor cells.
Human fibroblasts (PG98/5 and PO08) or tumor cells (LNZ308
glioblastoma and Me237 melanoma) were exposed to an
increasing concentration of 26, either (A) for 6 h and the
incorporation of radioactive thymidine (3HT) was performed
for the last 2 h or (B) for 24 h, and the MTT assay was
performed for the last 2 h, and the percent of growth was
calculated as the ratio of thymidine incorporation or MTT
reduction of treated to untreated cells. Results are shown as
means ( SD of triplicate wells of one representative experi-
ment out of three.
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amine R′NH2 (0.1-0.3 M) in 1,2-dichloroethane at 25 °C. After
the complete disappearance of the reagents (TLC monitoring),
the solution was poured into a saturated aqueous solution of
NaHCO3 (5 mL per mmol). The organic layer was collected,
and the aqueous layer was extracted with EtOAc (10 mL per
mmol, 3 times). The combined organic extracts were dried
(MgSO4). Solvent evaporation in vacuo and flash chromatog-
raphy on silica gel gave pure diamines.
Procedure 2: General Method for the Acidic Cleavage
of Boc and Acetonide Moieties. A 5% solution of protected
diamines in 4:1 CF3COOH/H2O or in 4 M aqueous HCl was
stirred at 25 °C for 1 h. After solvent evaporation in vacuo,
the residue was purified by flash chromatography on silica gel
or alumina.
tert-Butyl(3aR,4R,6aS)-4-({[(1R)-2-Hydroxy-1-phenylethyl]-
amino}methyl)-2,2-dimethyl tetrahydro-5H-[1,3]dioxolo-
[4,5-c]pyrrole-5-carboxylate ((-)-6a). Procedure 1: 5 (261
mg, 0.96 mmol), D-(-)-R-phenylglycinol (132 mg, 0.96 mmol),
NaBH(OAc)3 (285 mg, 1.34 mmol), ClCH2CH2Cl (10 mL). FC
(EtOAc): 281 mg (74%), 1.2:1 mixture of rotamers. 1H NMR
(400 MHz, MeOD) ä: 7.38-7.25 (m, 5H), 4.75-4.60 (m, 2H),
4.10 (dd, 1H), 4.03 (dd, 1H), 3.75 (m, 2H), 3.66-3.51 (m, 2H),
3.37 (m, 1H), 2.64-2.43 (m, 2H), 1.48, 1.40 (2s, 9H), 1.43 (s,
3H), 1.33 (s, 3H). 13C NMR (101 MHz, MeOD) ä: 157.3, 154.6,
142.9, 130.4, 129.6, 129.4, 113.4, 85.4, 84.9, 82.2, 82.1, 81.6,
80.9, 68.9, 68.7, 67.5, 67.2, 66.2, 65.8, 53.9, 53.6, 50-49, 29.5,
28.1, 25.9. MS (CI-NH3): 394 (16), 393 (M + H+, 12), 362 (3),
338 (12), 305 (15), 262 (6), 199 (10), 142 (42), 118 (100), 91
(95), 77 (26). Anal. (C21H32N2O5) C 64.49, H 8.07.
(2R,3R,4S)-2-({[(1R)-2-Hydroxy-1-phenylethyl]amino}-
methyl)pyrrolidine-3,4-diol ((+)-7a). Procedure 2: 6a (25
mg), 4 M HCl. FC (CH3CN/NH4OH 4:1): 16 mg (100%). 1H
NMR (400 MHz, MeOD) ä: 7.42-7.29 (m, 5H), 4.26 (ddd, 1H),
3.97 (dd, 1H), 3.83 (dd, 1H), 3.70 (dd, 1H), 3.64 (dd, 1H), 3.49-
3.43 (d and m, 2H), 3.25 (dd, 1H), 2.93 (dd, 1H), 2.78 (dd, 1H).
13C NMR (101 MHz, MeOD) ä: 142.6, 130.6, 129.6, 129.4, 75.5,
71.9, 68.3, 67.5, 63.7, 51.5, 48.1). MS (CI-NH3): 253 (M + H+,
9), 221 (8), 150 (7), 120 (100), 91 (17). Electrospray: 253.31.
Anal. (C13H20N2O3) C 61.76, H 7.95, N 11.08.
tert-Butyl(3aR,4R,6aS)-4-({[(1S)-2-Hydroxy-1-phenylethyl]-
amino}methyl)-2,2-dimethyl tetrahydro-5H-[1,3]dioxolo-
[4,5-c]pyrrole-5-carboxylate ((+)-6b). Procedure 1: 5 (97
mg, 0.36 mmol), L-(+)-R-phenylglycinol (49 mg, 0.36 mmol),
NaBH(OAc)3 (106 mg, 0.50 mmol), ClCH2CH2Cl (3 mL). FC
(EtOAc): 84 mg (60%), 1.7:1 mixture of rotamers.1H NMR (400
MHz, MeOD) ä: 7.37-7.26 (m, 5H), 4.76 (m, 1H), 4.56 (d, 1HR),
4.49 (d, 1Hâ), 4.14 (dd, 1Hâ), 4.00 (dd, 1HR), 3.76 (m, 2H), 3.68-
3.52 (m, 2H), 3.36 (m, 1H), 2.66 (m, 1H), 2.46 (dd, 1H), 1.50
(s, 3H), 1.43, 1.41 (2s, 9H), 1.30 (s, 3H). 13C NMR (101 MHz,
MeOD) ä: 157.2, 142.8, 130.4, 129.7, 129.5, 113.4, 85.7, 85.3,
82.2, 82.1, 81.7, 80.9, 68.8, 67.4, 66.3, 65.7, 54.4, 53.6, 50-49,
29.5, 28.1, 25.8. MS (CI-NH3): 394 (100), 393 (M + H+, 49),
362 (55), 338 (16), 306 (35), 262 (13), 199 (16), 150 (72), 91
(48). Anal. (C21H32N2O5) C 64.33, H 8.33, N 7.01.
(2R,3R,4S)-2-({[(1S)-2-Hydroxy-1-phenylethyl]amino}-
methyl)pyrrolidine-3,4-diol ((+)-7b). Procedure 2: 6b (30
mg), 4 M HCl. FC (CH3CN/NH4OH 4:1): 19 mg (100%). [R]58925
) +42, [R]57725 ) +46, [R]54625 ) +50, [R]43525 ) +85, [R]40525 )
+99 (c ) 0.55, H2O). 1H NMR (400 MHz, MeOD) ä: 7.42-
7.31 (m, 5H), 4.24 (ddd, 1H), 3.97 (dd, 1H), 3.83 (dd, 1H), 3.70
(dd, 1H), 3.64 (dd, 1H), 3.57 (ddd, 1H), 3.43 (dd, 1H), 3.27 (dd,
1H), 2.91 (dd, 1H), 2.80 (dd, 1H). 13C NMR (101 MHz, MeOD)
ä: 142.5, 130.6, 129.6, 129.5, 75.4, 72.0, 68.5, 66.9, 62.9, 51.8,
47.7. MS (CI-NH3): 253 (M + H+, 14), 221 (8), 235 (2), 195
(4), 138 (36), 116 (48), 98 (100), 84 (47). Anal. (C13H20N2O3) C
61.91, H 7.92, N 11.22.
tert-Butyl (3aR,4R,6aS)-4-({[(1R,2S)-2-Hydroxy-1,2-
diphenylethyl]amino}methyl)-2,2-dimethyltetrahydro-
5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-6c). Pro-
cedure 1: 5 (114 mg, 0.42 mmol), (1S,2R)-2-amino-1,2-
diphenylethanol (90 mg, 0.42 mmol), NaBH(OAc)3 (125 mg,
0.59 mmol), ClCH2CH2Cl (4 mL). FC (EtOAc/light petroleum
1:1): 120 mg (61%), 1.2:1 mixture of rotamers. 1H NMR (400
MHz, CDCl3) ä: 7.41-7.14 (m, 10H), 4.77 (d, 1H), 4.56 (m,
1H), 4.47 (m, 1H), 4.08 (m, 1Hâ), 3.94 (m, 1HR), 3.88 (d, 1H),
3.82 (d, 1HR), 3.73 (d, 1Hâ), 3.28 (m, 1H), 2.51 (m, 2H), 1.45,
1.36, 1.32 (3s, 15 H). 13C NMR (101 MHz, CDCl3) ä: 154.4,
154.2, 140.4, 139.2, 128.0, 127.9, 127.7, 126.7, 111.5, 83.8, 83.0,
79.7, 79.3, 78.6, 77.0, 69.1, 68.9, 63.8, 63.4, 52.1, 48.0, 47.4,
28.3, 26.9, 24.9. MS (CI-NH3): 469 (M + H+, 100), 413 (21),
361 (14), 305 (22), 261 (7), 186 (5), 142 (12). Anal. (C27H36N2O5)
C 69.29, H 7.83, N 5.95.
(2R,3R,4S)-2-({[(1R,2S)-2-Hydroxy-1,2-diphenylethyl]-
amino}methyl)pyrrolidine-3,4-diol ((+)-7c). Procedure 2:
6c (50 mg), 4:1 CF3COOH/H2O. FC (CH3CN/NH4OH 4:1): 35
mg (100%). 1H NMR (400 MHz, MeOD) ä: 7.29-7.12 (m, 10H),
5.06 (d, 1H), 4.17 (m, 1H), 4.07 (d, 1H), 3.88 (dd, 1H), 3.52 (m,
1H), 3.35 (dd, 1H), 3.23 (dd, 1H), 2.98 (dd, 1H), 2.67 (m, 1H).
13C NMR (101 MHz, MeOD) ä: 143.5, 130.8, 130.0, 129.7,
129.3, 128.8, 77.8, 75.8, 71.8, 71.2, 62.5, 51.7, 48.0. MS (CI-
NH3): 329 (M + H+, 57), 308 (2), 275 (3), 244 (3), 221 (100),
197 (9), 152 (6), 118 (35), 106 (66), 91 (40), 77 (49).
tert-Butyl (3aR,4R,6aS)-4-({[(1S,2R)-2-Hydroxy-1,2-
diphenylethyl]amino}methyl)-2,2-dimethyltetrahydro-
5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate ((-)-6d). Pro-
cedure 1: 5 (104 mg, 0.38 mmol), (1R,2S)-2-amino-1,2-
diphenylethanol (82 mg, 0.38 mmol), NaBH(OAc)3 (114 mg,
0.54 mmol), ClCH2CH2Cl (4 mL). FC (EtOAc/light petroleum
1:1): 69 mg (38%), 1.2:1 mixture of rotamers. 1H NMR (400
MHz, CDCl3) ä: 7.27-7.08 (m, 10H), 4.79 (d, 1HR), 4.75 (d,
1Hâ), 4.63 (m, 1H), 4.39 (d, 1Hâ), 4.34 (d, 1HR), 4.19 (dd,1Hâ),
4.02 (d, 1HR), 3.97 (dd, 1Hâ), 3.85-3.74 (m, 2H), 3.15 (m, 1H),
2.60-2.38 (m, 2H), 1.45, 1.42 (2s, 9H), 1.39, 1.28 (2s, 6H). 13C
NMR (101 MHz, CDCl3) ä: 155.0, 154.5, 140.1, 139.2, 128.3,
128.2, 128.1, 127.8, 127.6, 126.9, 126.7, 111.5, 83.9, 83.1, 80.0,
79.9, 79.3, 78.7, 77.2, 69.1, 68.1, 63.9, 62.8, 52.1, 51.8, 47.8,
47.2, 28.3, 26.9, 25.0. MS (CI-NH3): 469 (M + H+, 100), 413
(26), 361 (10), 305 (20), 261 (5), 186 (2), 142 (10), 84 (12). Anal.
(C27H36N2O5) C 69.30, H 7.69, N 5.94.
(2R,3R,4S)-2-({[(1S,2R)-2-Hydroxy-1,2-diphenylethyl]-
amino}methyl)pyrrolidine-3,4-diol ((+)-7d). Procedure 2:
6d (52 mg), 4:1 CF3COOH/H2O. FC (CH3CN/NH4OH 4:1): 36
mg (100%). 1H NMR (400 MHz, MeOD) ä: 7.30-7.14 (m, 10H),
4.95 (d, 1H), 4.20 (ddd, 1H), 3.96 (d, 1H), 3.88 (dd, 1H), 3.49
(ddd, 1H), 3.32 (dd, 1H), 3.22 (dd, 1H), 2.82 (dd, 1H), 2.76 (dd,
1H). 13C NMR (101 MHz, MeOD) ä: 143.8, 141.2, 130.6, 129.9,
129.7, 129.3, 129.0, 78.9, 75.4, 72.0, 70.5, 62.9, 51.7, 47.7. MS
(CI-NH3): 329 (M + H+, 23), 221 (19), 197 (44), 180 (10), 133
(33), 105 (100), 91 (61), 77 (52).
tert-Butyl (3aR,4R,6R,6aS)-4-({[(1R)-2-Hydroxy-1-
phenylethyl]amino}methyl)-6-[(methoxymethoxy)meth-
yl]-2,2-dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-
5-carboxylate ((-)-9). Dimethylsulfoxide (DMSO) (35 íL,
0.50 mmol, 2.4 equiv) was added to a solution of oxalyl chloride
(21 íL, 0.24 mmol, 1.15 equiv) in anhydrous dichloromethane
(1.5 mL) and cooled to -78 °C. After 20 min, alcohol 8 (72 mg,
0.21 mmol, 1 equiv) in solution in anhydrous dichloromethane
(2.5 mL) was added dropwise. After 20 min, triethylamine (144
íL, 1.04 mmol, 5 equiv) was added, and the mixture was
warmed to -30 °C for 20 min. The mixture was poured into
water (5 mL) and extracted with dichloromethane (5 mL, 3
times). The combined organic phases were washed with brine
(5 mL), dried over MgSO4, filtered, and concentrated in vacuo
to afford a crude aldehyde. Sodium triacetoxyborohydride (62
mg, 0.29 mmol, 1.4 equiv) was added portionwise to a stirred
solution of the crude aldehyde (0.21 mmol, 1 equiv) and d-(-)-
R-phenylglycinol (29 mg, 0.21 mmol, 1 equiv) in anhydrous
dichloroethane (2 mL). After being stirred at room temperature
overnight, the solution was poured into a saturated aqueous
solution of NaHCO3 (5 mL). The organic layer was collected,
and the aqueous layer was extracted with CH2Cl2 (5 mL, 3
times). The combined organic extracts were dried (MgSO4).
Solvent evaporation in vacuo and flash chromatography on
silica gel (EtOAc) afforded (-)-9 (63 mg, 65%, 2 steps). 1H NMR
(400 MHz, CDCl3) ä: 7.38-7.26 (m, 5H), 4.79 (dd, 1H), 4.67
(s, 2H), 4.64 (m, 1H), 4.39-3.99 (m, 2H), 3.89 (m, 1H), 3.81-
3.69 (m, 4H), 3.55 (dd, 1H), 3.39 (s, 3H), 2.66 (m, 2H), 1.53,
1.39 (2s, 15 H). 13C NMR (101 MHz, CDCl3) ä: 154.2, 140.2,
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128.7, 127.8, 127.0, 111.6, 96.8, 82.0, 80.3, 79.5, 66.8, 64.9, 64.1,
61.0, 55.2, 47.8, 28.3, 26.2, 25.0. MS (CI-NH3): 467 (M + H+,
100), 437 (17), 379 (9), 335 (6), 150 (7). Anal. (C24H38N2O7) C
61.88, H 8.24, N 6.12.
(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-({[(1R)-2-hydroxy-
1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol ((+)-
10). Procedure 2: 9 (26 mg), 4 M HCl. FC (CH3CN/NH4OH
4:1): 16 mg (100%). 1H NMR (400 MHz, D2O) ä: 7.58-7.50
(m, 5H), 4.35 (dd, 1H), 4.20 (m, 1H), 4.16 (dd, 1H), 4.03 (dd,
1H), 3.95 (m, 3H), 3.79 (m, 1H), 3.65 (m, 1H), 3.14 (bd, 2H).
13C NMR (101 MHz, D2O) ä: 138.8, 131.7, 131.5, 130.5, 76.6,
72.7, 66.7, 66.2, 64.3, 61.4, 60.4, 48. MS (CI-NH3): 283 (M +
H+, 12), 247 (2), 189 (3), 163 (15), 138 (100), 106 (54), 80 (9).
(2R)-2-(Diallylamino)-2-phenylethanol ((-)-11). NaH-
CO3 (2.45 g, 29.2 mmol, 2 equiv) and allyl bromide (5.05 mL,
58.3 mmol, 4 equiv) were added to a solution of D-(-)-R-
phenylglycinol (2 g, 14.6 mmol, 1 equiv) in THF/DMSO (40
mL/10 mL). A catalytic amount of tetrabutylammonium iodide
(1.62 g, 4.38 mmol, 0.3 equiv) was added, and the reaction
mixture was stirred at 60 °C for 3 h. Water (30 mL) was added
after the reaction warmed to room temperature. The reaction
mixture was extracted with CH2Cl2 (75 mL, 3 times), dried
(MgSO4), filtered, and concentrated in vacuo. Purification by
flash chromatography (EtOAc/light petroleum 1:1) afforded
(-)-11 as a pale yellow oil (2.70 g, 85%). 1H NMR (400 MHz,
MeOD) ä: 7.39-7.30 (m, 3H, 7.22-7.20 (m, 2H), 5.82 (dddd,
2H), 5.19 (m, 4H), 4.01 (m, 2H), 3.63 (dd, 1H), 3.40 (m, 2H),
2.73 (dd, 2H). 13C NMR (101 MHz, MeOD) ä: 136.4, 135.7,
129.0, 128.3, 127.8, 117.7, 63.4, 60.4, 52.4. MS (CI-NH3): 218
(M + H+, 100), 186 (32), 98 (4). Anal. (C14H19NO) C 77.51, H
8.93.
N,N-Diallyl-N-[(1R)-2-methoxy-1-phenylethyl]amine
((-)-12). Diallylamine 11 (169 mg, 0.78 mmol, 1 equiv) was
dissolved in anhydrous THF (3 mL), under argon atmosphere,
and the temperature was cooled to 0 °C. Sodium hydride (41
mg, 0.93 mmol, 1.2 equiv, 55% in oil) was added and the
reaction mixture was stirred at 0 °C for 10 min. Methyl iodide
(86 íL, 0.93 mmol, 1.2 equiv) was added, and the mixture was
allowed to warm to room temperature. After 2 h, the resulting
mixture was poured into a saturated aqueous solution of
NaHCO3 (5 mL) and the aqueous layer was extracted with
EtOAc (5 mL, 3 times). The combined organic extracts were
dried (MgSO4), filtered, and concentrated in vacuo. Flash
chromatography on silica gel (EtOAc/light petroleum 1:9)
afforded (-)-12 (122 mg, 68%). 1H NMR (400 MHz, CDCl3) ä:
7.37-7.26 (m, 5H), 5.91-5.82 (m, 2H), 5.16 (m, 4H), 4.04 (t,
1H), 3.81 (dd, 1H), 3.71 (dd, 1H), 3.35 (s, 3H, Me), 3.28 (dd,
2H), 2.99 (dd, 2H). 13C NMR (101 MHz, CDCl3) ä: 139.3, 136.6,
128.5, 128.1, 127.1, 117.0, 73.8, 62.7, 58.9, 53.2. MS (CI-NH3):
232 (M + H+, 100), 186 (97), 135 (12), 117 (2), 91 (11). Anal.
(C15H21NO) C 72.71, H 9.12, N 6.11.
N,N-Diallyl-N-[(1R)-2-(benzyloxy)-1-phenylethyl]-
amine ((-)-13). Diallylamine 11 (307 mg, 1.41 mmol, 1 equiv)
was dissolved in anhydrous THF (5 mL), under argon atmo-
sphere, and the temperature was cooled to 0 °C. Sodium
hydride (74 mg, 1.70 mmol, 1.2 equiv, 55% in oil) was added,
and the mixture was stirred at 0 °C for 10 min. Benzyl bromide
(201 íL, 1.70 mmol, 1.2 equiv) was added, and the mixture
was allowed to warm to room temperature for 12 h. The
resulting mixture was poured into a saturated aqueous solu-
tion of NaHCO3 (10 mL), and the aqueous layer was extracted
with EtOAc (15 mL, 3 times). The combined organic extracts
were dried (MgSO4), filtered, and concentrated in vacuo. Flash
chromatography on silica gel (EtOAc/light petroleum 1:9)
afforded (-)-13 (430 mg, 100%). 1H NMR (400 MHz, CDCl3)
ä: 7.44-7.25 (m, 10H), 5.95-5.85 (m, 2H), 5.24-5.15 (m, 4H),
4.55 (s, 2H), 4.13 (t, 1H), 3.92 (dd, 1H), 3.82 (dd, 1H), 3.31
(dd, 2H), 3.07 (dd, 2H). 13C NMR (101 MHz, CDCl3) ä: 138.3,
136.4, 128.5, 128.2, 128.0, 127.5, 127.4, 127.0, 117.0, 73.0, 71.2,
63.0, 53.2. MS (CI-NH3): 308 (M + H+, 71), 186 (100), 144
(6), 91 (60).
(2R,3R,4S)-2-({[(1R)-2-Methoxy-1-phenylethyl]amino}-
methyl)pyrrolidine-3,4-diol ((+)-18). A mixture of Pd(dba)2
(4.11  10-5 mol) and DPPB (8.22  10-5 mol) in THF (0.5
mL) was stirred at room temperature, under argon atmosphere
for 15 min. The so-formed catalyst and 2-mercaptobenzoid acid
(2.2 equiv, 0.904 mmol) were added to the solution of 12 (95
mg, 0.411 mmol) in anhydrous THF (3 mL), and the reaction
was stirred at 60 °C for 12 h. The mixture was poured into a
1 M HCl solution (10 mL) and extracted with EtOAc (10 mL,
2 times). The aqueous layer was treated with 1 M NaOH and
extracted with EtOAc (10 mL, 3 times). The combined organic
extracts were dried (MgSO4) and concentrated in vacuo to
afford 15 (62 mg, 100% crude). Procedure 1 was applied on 5
(111 mg, 0.41 mmol) and 15 (62 mg, 0.41 mmol) in the presence
of NaBH(OAc)3 (122 mg, 1.34 mmol) in ClCH2CH2Cl (3 mL).
FC (EtOAc/light petroleum 1:1): 123 mg (74%), 1.4:1 mixture
of rotamers. This intermediate was treated according to
procedure 2 in 4:1 CF3COOH/H2O. FC (CH3CN/NH4OH 4:1):
(+)-18, 81 mg (100%).
Data for Intermediate tert-Butyl (3aR,4R,6aS)-4-
({[(1R)-2-Methoxy-1-phenylethyl]amino} methyl)-2,2-
dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-car-
boxylate. 1H NMR (400 MHz, MeOD) ä: 7.39-7.26 (m, 5H),
4.69 (m, 1H), 4.60 (d, 1HR), 4.55 (d, 1Hâ), 4.09 (dd, 1Hâ), 4.04
(dd, 1HR), 3.88 (m, 1H), 3.76 (m, 1H), 3.50 (m, 2H), 3.38 (s,
3H), 3.33 (m, 1H), 2.60-2.40 (m, 2H), 1.48 (s, 3H), 1.41 (s, 9
H), 1.31 (s, 3H). 13C NMR (101 MHz, MeOD) ä: 157.4, 157.1,
142.5, 130.4, 129.6, 129.5, 113.4, 85.4, 84.9, 82.3, 82.1, 81.6,
80.9, 79.4, 79.2, 66.2, 65.7, 64.9, 64.5, 59.9 53.8, 53.3, 50-49,
29.5, 28.1, 25.9. MS (CI-NH3): 407 (M + H+, 100), 361 (10),
305 (5), 164 (9), 106 (3). Anal. (C22H34N2O5) C 64.95, H 8.50.
Data for (+)-18. 1H NMR (400 MHz, MeOD) ä: 7.50-7.37
(m, 5H), 4.26 (m, 1H), 4.23 (ddd, 1H), 3.98 (dd, 1H), 3.68 (m,
2H), 3.63 (m, 1H), 3.50 (dd, 1H), 3.42 (s, 3H), 3.29 (dd, 1H),
3.20 (m, 1H), 3.08 (dd, 1H). 13C NMR (101 MHz, MeOD) ä:
138.4, 131.0, 130.8, 130.0, 76.7, 75.9, 71.4, 65.0, 61.3, 60.2, 52.0,
47.9. CI-MS (CI-NH3): 267 (M + H+, 100), 221 (34), 164 (22),
152 (9), 135 (35), 120 (39), 106 (19), 95 (10).
(2R,3R,4S)-2-({[(1R)-2-(Benzyloxy)-1-phenylethyl]-
amino}methyl)pyrrolidine-3,4-diol ((-)-19). A mixture of
Pd(dba)2 (3.5  10-5 mol) and DPPB (7.0  10-5 mol) in THF
(0.5 mL) was stirred at room temperature, under argon
atmosphere for 15 min. The so-formed catalyst and 2-mercap-
tobenzoid acid (2.2 equiv, 0.7 mmol) were added to the solution
of 13 (108 mg, 0.35 mmol) in anhydrous THF (3 mL), and the
reaction was stirred at 60 °C for 12 h. The mixture was poured
into a 1 M HCl solution (10 mL) and extracted with EtOAc
(10 mL, 2 times). The aqueous layer was treated with 1 M
NaOH and extracted with EtOAc (10 mL, 3 times). The
combined organic extracts were dried (MgSO4) and concen-
trated in vacuo to afford 16 (79 mg, 100% crude). Procedure 1
was applied on 5 (94 mg, 0.35 mmol) and 16 (79 mg, 0.35
mmol) in the presence of NaBH(OAc)3 (103 mg, 0.49 mmol) in
ClCH2CH2Cl (2.5 mL). FC (EtOAc/light petroleum 1:1): 101
mg (60%), 1.1:1 mixture of rotamers. This intermediate was
treated according to procedure 2 in 4:1 CF3COOH/H2O. FC
(CH3CN/NH4OH 4:1): (-)-19, 72 mg (100%).
Data for Intermediate tert-Butyl (3aR,4R,6aS)-4-
({[(1R)-2-(Benzyloxy)-1-phenylethyl] amino}methyl)-2,2-
dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-car-
boxylate. 1H NMR (400 MHz, MeOD) ä: 7.39-7.26 (m, 10H),
4.77-4.60 (m, 2H), 4.56 (s, 2H), 4.14-4.02 (m, 1H), 3.92 (m,
1H), 3.76 (d, 1HR), 3.74 (d, 1Hâ), 3.55 (m, 2H), 3.36 (m, 1H),
2.61-2.42 (m, 2H), 1.47, 1.38 (2s, 9H), 1.42 (s, 3H), 1.31 (s,
3H). 13C NMR (101 MHz, MeOD): 157.3, 157.1, 142.6, 130.4,
130.3, 129.8, 129.6, 129.5, 113.4, 85.4, 85.0, 82.3, 82.1, 81.6,
80.9, 77.0, 76.9, 75.0, 66.2, 65.8, 65.1, 64.6, 53.9, 53.4, 50-49,
29.5, 28.1, 25.9. MS (CI-NH3): 484 (M + H+, 100), 428 (3),
362 (62), 305 (18), 241 (6), 142 (14), 91 (30). Anal. (C28H38N2O5)
C 67.55, H 7.66.
Data for (-)-19. 1H NMR (400 MHz, MeOD) ä: 7.42-7.29
(m, 10H), 4.56 (s, 2 H), 4.21 (dd, 1 H), 3.96 (dd, 1H), 3.91 (dd,
1H), 3.63 (m, 2H), 3.40 (m, 2 H), 3.19 (dd, 1H), 2.88 (dd, 1H),
2.73 (dd, 1H). 13C NMR (101 MHz, MeOD) ä: 142.6, 140.2,
130.6, 130.3, 129.9, 129.7, 129.5, 76.7, 75.6, 75.2, 72.0, 65.3,
63.7, 51.5, 48.4. MS (CI-NH3): 343 (M + H+, 32), 306 (3), 229
(11), 195 (7), 159 (6), 120 (38), 106 (67), 91 (100).
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Data for (2S)-2-({[(2R, 3S, 4S)-3,4-Dihydroxypyrroli-
din-2-yl]methyl}amino)-2-phenylethyl 2-Fluorobenzoate
((-)-23). 1H NMR (400 MHz, MeOD) ä: 7.88 (m, 1H), 7.66-
7.62 (m, 1H), 7.48-7.22 (m, 7H), 4.50 (m, 2H), 4.22 (ddd, 1H),
4.14 (t, 1H, 3J ) 6.1 Hz, H-C(1′′)), 3.96 (dd, 1H), 3.48-3.38
(m, 2H), 3.23 (dd, 1H), 2.98 (dd, 1H), 2.75 (dd, 1H). 13C NMR
(101 MHz, MeOD) ä: 167.1, 141.2, 136.3, 136.2, 133.1, 129.8,
129.1, 128.6, 125.4, 118.1, 117.9, 74.8, 71.2, 69.7, 63.3, 62.7,
50.8, 47.5. MALDI-TOF: 375 (M + H)+.
Data for (2S)-2-({[(2R, 3S, 4S)-3,4-Dihydroxypyrroli-
din-2-yl]methyl}amino)-2-phenylethyl 4-Fluorobenzoate
((+)-24). 1H NMR (400 MHz, MeOD) ä: 8.05 (m, 2H), 7.48-
7.33 (m, 5H), 7.22 (m, 1H), 4.53 (dd, 1H), 4.45 (dd, 1H), 4.22
(m, 1H), 4.15 (m, 1H), 3.95 (dd, 1H), 3.48 (ddd, 1H), 3.41 (dd,
1H), 3.24 (dd, 1H), 2.99 (dd, 1H), 2.74 (dd, 1H). 13C NMR (101
MHz, MeOD) ä: 173.0, 141.3, 133.4, 130.0, 129.8, 129.4, 129.0,
128.6, 116.7, 74.8, 71.1, 69.5, 63.4, 62.7, 50.7, 47.6. MALDI-
TOF: 375 (M + H)+.
Data for (2S)-2-({[(2R, 3S, 4S)-3,4-Dihydroxypyrroli-
din-2-yl]methyl}amino)-2-phenylethyl 3-Bromobenzoate
((-)-25). 1H NMR (400 MHz, MeOD) ä: 8.11 (s, 1H), 7.97 (d,
1H), 7.80 (dd, 1H), 7.49-7.41 (m, 5H), 7.35 (d, 1H), 4.55 (dd,
1H), 4.46 (dd, 1H), 4.21 (ddd, 1H), 4.14 (dd, 1H), 3.95 (dd, 1H),
3.48-3.42 (dd, 1H), 3.41-3.34 (m, 1H), 3.22 (dd, 1H), 2.98 (dd,
1H), 2.72 (dd, 1H). 13C NMR (101 MHz, MeOD) ä: 163.3 ,
144.4, 141.3, 138.8, 137.2, 133.4, 131.5,129.9, 129.3, 129.1,
128.6, 74.9, 71.2, 69.7, 63.4, 62.7, 50.8, 47.7. MALDI-TOF: 437
(M + 2)+, 435 M+¥.
Data for (2S)-2-({[(2R, 3S, 4S)-3,4-Dihydroxypyrroli-
din-2-yl]methyl}amino)-2-phenylethyl 4-Bromobenzoate
((-)-26). 1H NMR (400 MHz, MeOD) ä: 7.90 (d, 2H), 7.68 (d,
2H), 7.48-7.40 (m, 4H), 7.28 (m, 1H), 4.54 (dd, 1H), 4.46 (dd,
1H), 4.22 (m, 1H), 4.14 (dd, 1H), 3.95 (dd, 1H), 3.46 (ddd, 1H),
3.41 (m, 1H, H-C(5)), 3.23 (dd, 1H), 2.99 (dd, 1H), 2.73 (dd,
1H). 13C NMR (101 MHz, MeOD) ä: 170.0, 141.3, 133.0, 132.3,
130.3, 129.9, 129.2, 129.1, 128.6, 74.8, 71.1, 69.6, 63.4, 62.7,
50.7, 47.7. MALDI-TOF: 437 (M + 2)+, 435 M+¥.
Data for 3-Bromo-N-[(2S)-2-({[(2R,3S,4R)-3,4-dihydroxy-
pyrrolidin-2-yl]methyl}amino)-2-phenylethyl]benzamide
((+)-29). 1H NMR (400 MHz, MeOD): 7.93 (s, 1H), 7.72 (dd,
2H), 7.41-7.31 (m, 6H), 4.25 (m, 1H), 3.99 (m, 2H), 3.67 (dd,
1H), 3.59 (dd, 1H), 3.51-3.43 (m, 2H, 3.28 (dd, 1H), 2.96 (dd,
1H), 2.73 (dd, 1H). 13C NMR (101 MHz, MeOD): 169.0, 142.4,
137.7, 135.6, 131.4, 129.8, 128.9, 128.4, 127.1, 123.5, 74.7, 71.1,
64.1, 62.7, 50.6, 47.4, 46.8. MALDI-TOF: 436 [(M + 2)+], 434
(M+¥).
Biology. (A) Inhibition of Commercially Purified Plant
Glycosidases. The experiments were performed essentially
as previously described.18 Briefly, 0.01-0.5 units/mL of enzyme
(1 unit ) 1 ímol of glycoside hydrolyzed/min), preincubated
for 5 min at 20 °C with the inhibitor, and increasing concen-
tration of aqueous solution of the appropriate p-nitrophenyl
glycoside substrates buffered to the optimum pH of the enzyme
were incubated for 20 min at 37 °C (45 °C for the amyloglu-
cosidases). The reaction was stopped by the addition of a 2.5
volume of 0.2 M sodium borate buffer pH 9.8. The p-nitrophe-
nolate formed was quantified at 410 nm, and IC50 values were
calculated or double-reciprocal (Lineweaver-Burk) plots were
used to determine the inhibition characteristics.
(B) Cell Cultures and Treatments. Human LN18 and
LNZ308 glioblastoma cell lines25 were routinely maintained
in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Basel,
Switzerland) containing 4.5 g/glucoses, 5% fetal calf serum
(FCS, Gibco), and antibiotics. Human Me237 and Me275 cell
lines26 were grown in RPMI medium (Gibco) containing 10%
FCS and antibiotics. Human primary fibroblasts were pre-
pared from surgical skin (PG 98/5) or lung (PO 08) biopsies
using the explant technique and grown in DMEM medium
containing 4.5 g/L glucose, 10% FCS, and antibiotics. For the
experiments, cells were grown in 48 well plates (Costar,
Corning, NY) for 24-72 h in the presence of FCS, and then
exposed for the indicated time to increasing concentrations of
pyrrolidine derivatives (from 0 to 300 íM, stock solutions in
methanol/phosphate buffered saline (1:20)) in fresh complete
medium. Then either metabolically active cells were quantified
using the MTT assay (cf. below) or DNA synthesis and protein
synthesis were evaluated using [3H]-thymidine or [3H]-leucine
incorporation (cf. below). Experiments were performed in
triplicate wells and were repeated at least three times. Means
( SD have been calculated.
(C) Evaluation of Cell Proliferation by the MTT Assay.
MTT (Sigma, Buchs, Switzerland) was used to quantify the
number of metabolically active cells. The cells were exposed
to 0.2 mg/mL MTT in DMEM medium for 2 h following
treatment with pyrrolidine, the supernatant was aspirated,
and the precipitated formazan was dissolved in 0.1 N HCl in
2-propanol and quantified at 540 nm in a multiwell plate
reader (iEMS Reader MF, Labsystems, Bioconcepts, Switzer-
land).
(D) Evaluation of DNA and Protein Synthesis. Thymi-
dine and leucine incorporation were used to assess DNA and
protein synthesis, respectively. [3H]-Thymidine (Amersham-
Pharmacia, Du¨bendorf, Switzerland, 400 nCi/well) or [3H]-Leu
(American Radiolabeled Chemicals, St. Louis MO, 400 nCi/
puit) were added to treated or control cells for the last 2 h of
incubation with the pyrrolidine derivatives. The cell layer was
washed and precipitated with 10% trichloracetic acid, the
precipitate was dissolved in 1% sodium dodecyl sulfate in 0.1
N NaOH; then 5 mL of scintillation cocktail (Optiphase,
Wallac, Regensdorf, Switzerland) was added, and the radio-
activity was counted in a â-counter (WinSpectral, Wallac).
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